The most commonly used cells in ACT are tumor-infiltrating lymphocytes (TILs) and engineered T cells. TILs are extracted directly from the tumor, expanded in the laboratory, and then infused back into the patient. Engineered T cells, such as CAR-T cells, are genetically modified to express specific receptors that enhance their ability to recognize and kill cancer cells.
